SpliSense
PrivateLast Round
Strategic
Apr 3, 2024
Total Funding Raised
$37M
Momentum Score
25 /100
Company Overview
SpliSense is a biotechnology company that develops innovative drugs aimed at correcting splicing mutations in genetic diseases, specifically targeting the CFTR gene to provide effective treatments for cystic fibrosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SpliSense Comps
Public and private peers based on sector, stage, and business model.
SpliSense Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Apr 3, 2024 | ||||
| Series B | May 13, 2021 |
SpliSense Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Israel Biotech Fund | Series B, Strategic |
| OrbiMed | Strategic, Series B |
| Integra Holdings | Series B, Strategic |
| Cystic Fibrosis Foundation | Series B, Strategic |
SpliSense Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about SpliSense's valuation, stock price, and market status.
